Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter
Professionals >> Visit The Body PROThe Body en Espanol
Home Page for TheBody.com, the Complete HIV/AIDS Resource What's New About HIV Ask the Experts About HIV HIV/AIDS Blogs Connect With Others About HIV Just Diagnosed With HIV HIV Treatment HIV Prevention Living With HIV Personal Stories of People With HIV
  
  • Email Email
  • Glossary Glossary
The Body Covers: The XIV International AIDS Conference
Durability and Tolerability of ABC/AZT/3TC

Coverage provided by Keith Henry, M.D.

July 9, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

  • Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine (ABC/AZT/3TC) Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (TuPeB4453)
    Authored by P. Gute, B. Dauer, T. Stark, A. Haberl, M. Bickel, V. Rickerts, B. Jennings, S. Staszewski
    View the original abstract


Many cohort studies have reported a high frequency of changes in HAART regimens over time (i.e., percent of patients who change their first regimen within the first 18 months). Gute and colleagues from Frankfurt evaluated 183 patients started on abacavir/zidovudine/lamivudine (ABC/AZT/3TC) as their first regimen for whom CD4 and RNA data was available. Sixty percent were still on their initial regimen after a median of 20 months (40 percent switched or stopped).

The initial median viral load for the cohort was 5.05 log and the CD4 count was 217. There were eight cases of abacavir hypersensitivity reaction (4 percent). AZT was switched to d4T in 17 patients due to intolerance. Overall, 29 patients (15 percent) stopped HAART completely. The authors conclude that this triple NRTI regimen is simple and well tolerated.

I would comment that the results are equivalent or superior compared to many published reports regarding the tolerability/durability of the initial regimen. The virologic criteria for success was not discussed (i.e., didn't use less than 50 copies/ml as the target), so that may have impacted the results.


A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

See Also
HIV Medications: When to Start and What to Take -- A Guide From TheBody.com
More Research on First-Line HIV Treatment



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement